Clinical Trials Browser

Oropharyngeal Neoplasms

NCT04590963 2026-03-13

INTERLINK-1

Phase 3 Active not recruiting

370 enrolled 21 charts

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Laryngeal Diseases

NCT03570021 2026-03-06

ESTIMABL3

Phase 3 Active not recruiting

352 enrolled

Head & Neck

Thyroid Neoplasms

NCT05721755 2026-03-05

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Phase 3 Active not recruiting

290 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Hypopharyngeal Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms

NCT00588770 2026-03-03

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Phase 3 Active not recruiting

403 enrolled 10 charts

Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Salivary Gland Neoplasms, Tongue Neoplasms

NCT07435324 2026-02-27

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Phase 3 Active not recruiting

161 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT01893307 2026-02-24

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

Phase 3 Active not recruiting

440 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04967391 2026-02-18

Tumescence in HNC Skin Graft Reconstruction

Phase 3 Active not recruiting

58 enrolled

Head & Neck

Head and Neck Neoplasms

NCT04940052 2025-12-02

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Phase 3 Active not recruiting

153 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer (DTC)

NCT07248670 2025-11-25

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

Phase 3 Active not recruiting

252 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT01266044 2025-10-27

Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia

Phase 3 Active not recruiting

435 enrolled

Head & Neck

Head and Neck Neoplasms, Oropharyngeal Neoplasms, Xerostomia

NCT06118333 2025-09-30

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

386 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03690388 2025-09-25

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

Phase 3 Active not recruiting

187 enrolled 13 charts 1 FDA

EndocrineHead & Neck

Thyroid cancer, follicular, Thyroid Cancer, Papillary, Thyroid Neoplasms, Adenocarcinoma, Follicular

NCT04384627 2025-09-04

NPC-GTV

Phase 3 Active not recruiting

445 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03765918 2025-08-20

MK-3475-689

Phase 3 Active not recruiting

714 enrolled 90 charts 1 FDA

Head & Neck

Parkinson Disease 4, Autosomal Dominant Lewy Body, Head and Neck Neoplasms

NCT04907370 2025-07-16

DIAMOND

Phase 3 Active not recruiting

532 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05294172 2025-05-30

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

295 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Neoplasm Metastasis, Recurrence

NCT04456322 2025-05-14

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

381 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02998385 2025-05-07

SANTAL

Phase 3 Active not recruiting

342 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT02999087 2025-05-07

REACH

Phase 3 Active not recruiting

707 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03576417 2025-05-07

NIVOPOSTOP

Phase 3 Active not recruiting

680 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT04974398 2025-04-13

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

296 enrolled 1 FDA

Head & Neck

Nasopharyngeal Carcinoma

NCT05304468 2025-03-21

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

Phase 3 Active not recruiting

452 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05587374 2025-01-23

GEMSTONE

Phase 3 Active not recruiting

490 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT03769506 2025-01-16

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

Phase 3 Active not recruiting

135 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT03840421 2025-01-13

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

468 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Head and Neck Neoplasms, Nasopharyngeal Diseases, Nasopharyngeal Neoplasms

NCT05869227 2024-12-30

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

166 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02460887 2024-12-03

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

Phase 3 Active not recruiting

236 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04116047 2024-07-29

CompARE

Phase 3 Active not recruiting

785 enrolled

Head & Neck

Oropharyngeal Neoplasms

NCT05211232 2024-04-18

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

450 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT03427827 2024-04-09

DIPPER

Phase 3 Active not recruiting

450 enrolled

Head & Neck

Nasopharyngeal Neoplasms

NCT03519048 2024-03-26

SURVEILL'ORL

Phase 3 Active not recruiting

197 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck

NCT03306121 2023-05-22

TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma

Phase 3 Active not recruiting

322 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT01837745 2023-05-17

ESTIMABL2

Phase 3 Active not recruiting

776 enrolled

EndocrineHead & Neck

Low Risk Differentiated Thyroid Cancer

Clinical Trials

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

INTERLINK-1

ESTIMABL3

Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck

Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma

Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients With Stage III-IVB Oropharyngeal Cancer

Tumescence in HNC Skin Graft Reconstruction

Study of Efficacy and Safety of Dabrafenib in Combination With Trametinib in Previously Treated Patients With Metastatic, Radio-active Iodine Refractory BRAF V600E Mutation Positive Differentiated Thyroid Cancer

Concurrent Chemoradiotherapy With or Without Metronomic Capecitabine in High-Risk T1-2N1M0 NPC

Controlled Trial Of Acupuncture To Prevent Radiation-Induced Xerostomia

A Study Comparing BL-B01D1 With Physician's Choice of Chemotherapy in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NPC-GTV

MK-3475-689

DIAMOND

KL-A167 Injection Combined With Cisplatin and Gemcitabine vs Placebo Combined With Cisplatin and Gemcitabine in the Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Radiotherapy Plus Nimotuzumab or Cisplatin in Nasopharyngeal Carcinoma

SANTAL

REACH

NIVOPOSTOP

A Study of Penpulimab (AK105) in the First-line Treatment of Recurrent or Metastatic Nasopharyngeal Carcinoma

Reduced-dose Versus Standard Dose Radiotherapy for Nasopharyngeal Carcinomain

GEMSTONE

ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy

GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma

Maintenance Therapy With Toripalimab Combined With Capecitabine/Placebo for Recurrent and Metastatic Nasopharyngeal Carcinoma

The Role of Induction Gemcitabine and Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma in the Era of IMRT

CompARE

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

DIPPER

SURVEILL'ORL

TPF+CCRT vs.CCRT+PF in High Risk Nasopharyngeal Carcinoma

ESTIMABL2